Iron and peripheral arterial disease: Revisiting the iron hypothesis in a different light

Vascular Medicine

Volumn 8, Issue 3, 2003, Pages 203-210

  Ramakrishna, Gautam ^a   Rooke, Thorn W ^a   Cooper, Leslie T ^a  

^a MAYO CLINIC   (United States)

Author keywords

Atherosclerosis; Coronary artery disease; Iron; Oxidative stress; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; ASCORBIC ACID; DEFEROXAMINE; EDETIC ACID; IRON; IRON DEXTRAN; MAGNESIUM SULFATE; RINGER LACTATE SOLUTION; SODIUM CHLORIDE; VITAMIN B COMPLEX;

ARTERY DISEASE; ATHEROSCLEROSIS; BODY BURDEN; CARDIOVASCULAR DISEASE; CLAUDICATION; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; HEART MUSCLE FIBROSIS; HUMAN; HYPERCHOLESTEROLEMIA; IRON BLOOD LEVEL; IRON METABOLISM; IRON OVERLOAD; IRON RESTRICTION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHLEBOTOMY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ARTERIOSCLEROSIS; DISEASE MODELS, ANIMAL; HUMANS; IRON; IRON OVERLOAD; OXIDATIVE STRESS;

EID: 1242340476     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x03vm493ra     Document Type: Review

References (96)

1. Corti MC, Gaziano M, Hennekens CH. Iron status and risk of cardiovascular disease. Ann Epidemiol 1997; 7: 62-68.
2. Bathum L, Christiansen L, Nybo H et al. Association of mutations in the hemochromatosis gene with shorter life expectancy. Arch Intern Med 2001; 161: 2441-44.
3. Yuan XM, Brunk UT. Iron and LDL-oxidation in atherogenesis. APMIS 1998; 106: 825-42.
4. Horwitz L, Rosenthal E. Iron-mediated cardiovascular injury. Vasc Med 1999; 4: 93-99.
5. Chau L. Iron and atherosclerosis. Proceedings of the National Science Council, Republic of China - Part B. Life Sci 2000; 24: 151-55.
6. Meyers DG. The iron hypothesis: does iron play a role in atherosclerosis? Transfusion 2000; 40: 1023-29.
7. Gackowski D, Kruszewski M, Jawien A, Ciecierski M, Olinski R. Further evidence that oxidative stress may be a risk factor responsible for the development of atherosclerosis. Free Radic Biol Med 2001; 31: 542-47.
8. Rice-Evans C, Burdon R. Free radical-lipid interactions and their pathological consequences. Prog Lipid Res 1993; 32: 71-110.
9. Halliwell B, Gutteridge J. Role of free radicals and catalytic metal ions in human disease: an overview. In: Packer L, Glazer A (eds). Methods in enzymology, vol. 186. San Diego: Academic Press, 1990: 1-85.
10. Lamb D, Leake D. Iron released from transferring at acidic pH can catalyse the oxidation of low density lipoprotein. FEBS Lett 1994; 352: 15-18.
11. Leake D, Rankin S. The oxidative modification of low-density lipoproteins by macrophages. Biochem J 1990; 270: 741-48.
12. Steinbrecher U, Zhang H, Lougheed M. Role of oxidatively modified LDL in atherosclerosis. Free Radic Biol Med 1990; 9: 155-68.
13. Steinberg D, Pathasarathy S, Carew T, Khoo J, Witzum J. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenecity. N Engl J Med 1989; 320: 915-24.
14. De Valk B, Marx J. Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med 1999; 159: 1542-48.
15. Reif DW, Simmons RD. Nitric oxide mediates iron release from ferritin. Arch Biochem Biophys 1990; 283: 537-41.
16. Ambrosio G, Tritto I, Golino P. Reactive oxygen metabolites and arterial thrombosis. Cardiovasc Res 1997; 34: 445-52.
17. Pratico D, Pasin M, Barry OP et al. Iron-dependent human platelet activation and hydroxyl radical formation: involvement of protein kinase C. Circulation 1999; 99: 3118-24.
18. Day SM, Duquaine D, Mundada LV et al. Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. Circulation 2003; 107: 2601-606.
19. Voogd A, Sluiter W, Koster JF. The increased susceptibility to hydrogen peroxide of the (post-)ischemic rat heart is associated with the magnitude of the low molecular weight iron pool. Free Radic Biol Med 1994; 16: 453-58.
20. Thong P, Selley M, Watt F. Elemental changes in atherosclerotic lesions using nuclear microscopy. Cell Mol Biol 1996; 42: 103-10.
21. Vlad M, Caseanu E, Uza G, Petrescu M. Concentration of copper, zinc, chromium, iron, and nickel in the abdominal aorta of patients deceased with coronary artery disease. J Trace Elem Electrolytes Health Dis 1994; 8: 111-14.
22. Swain J, Gutteridge JM. Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosclerotic material. FEBS Lett 1995; 368: 513-15.
23. Smith C, Mitchinson MJ, Aruoma OI, Halliwell B. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J 1992; 286: 901-905.
24. Evans PJ, Smith C, Mitchinson MJ, Halliwell B. Metal ion release from mechanically-disrupted human arterial wall. Implications for the development of atherosclerosis. Free Radic Res 1995; 23: 465-69.
25. Pang JH, Jiang MJ, Chen YL et al. Increased ferritin gene expression in atherosclerotic lesions. J Clin Invest 1996; 97: 2204-12.
26. Yuan XM, Anders WL, Olsson AG, Brunk UT. Iron in human atheroma and LDL oxidation by macrophages following erythrophagocytosis. Atherosclerosis 1996; 124: 61-73.
27. Olinski R, Zastawny T, Budzbon J, Skokowski J, Zegarski W, Dizdaroglu M. DNA base modifications in chromatin of human cancerous tissues. FEBS Lett 1992; 309: 193-98.
28. De Flora S, Izzotti A, Walsh D, Degan P, Petrilli GL, Lewtas J. Molecular epidemiology of atherosclerosis. FASEB J 1997; 11: 1021-31.
29. Collins AR, Gedik CM, Olmedilla B, Southon S, Bellizzi M. Oxidative DNA damage measured in human lymphocytes: large differences between sexes and between countries, and correlations with heart disease mortality rates. FASEB J 1998; 12: 1397-400.
30. Porreca E, Ucchino S, Di Febbo C et al. Antiproliferative effect of desferrioxamine on vascular smooth muscle cells in vitro and in vivo. Arterioscler Thromb 1994; 14: 299-304.
31. Hagen PO, Davies MG, Schuman RW, Murray JJ. Reduction of vein graft intimal hyperplasia by ex vivo treatment with desferrioxamine manganese. J Vasc Res 1992; 29: 405-409.
32. Araujo JA, Romano EL, Brito BE et al. Iron overload augments the development of atherosclerotic lesions in rabbits. Arterioscler Thromb Vasc Biol 1995; 15: 1172-80.
33. Van Lenten BJ, Prieve J, Navab M, Hama S, Lusis AJ, Fogelman AM. Lipid-induced changes in intracellular iron homeostasis in vitro and in vivo. J Clin Invest 1995; 95: 2104-10.
34. Lee TS, Shiao MS, Pan CC, Chau LY. Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. Circulation 1999; 99: 1222-29.
35. Ponraj D, Makjanic J, Thong PS, Tan BK, Watt F. The onset of atherosclerotic lesion formation in hypercholesterolemic rabbits is delayed by iron depletion. FEBS Lett 1999; 459: 218-22.
36. Dabbagh AJ, Shwaery GT, Keaney JF Jr, Frei B. Effect of iron overload and iron deficiency on atherosclerosis in the hypercholesterolemic rabbit. Arterioscler Thromb Vasc Biol 1997; 17: 2638-45.
37. Juan SH, Lee TS, Tseng KW et al. Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001; 104: 1519-25.
38. Ishizaka N, Saito K, Mitani H et al. Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation. Circulation 2002; 106: 1840-46.
39. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981; i: 1293-94.
40. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976; 85: 447-52.
41. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med 1978; 89: 157-61.
42. Sullivan JL. Iron, hematocrit, and the sex difference in heart disease. Arch Pathol Lab Med 1993; 117: 966-67.
43. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992; 86: 803-11.
44. Salonen JT, Nyyssonen K, Salonen R. Body iron stores and the risk of coronary heart disease. N Engl J Med 1994; 331: 1159; discussion 1160.
45. Tuomainen TP, Punnonen K, Nyyssonen K, Salonen JT. Association between body iron stores and the risk of acute myocardial infarction in men. Circulation 1998; 97: 1461-66.
46. Klipstein-Grobusch K, Koster JF, Grobbee DE et al. Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr 1999; 69: 1231-36.
47. Lauffer RB. Iron stores and the international variation in mortality from coronary artery disease. Med Hypotheses 1991; 35: 96-102.
48. Morrison HI, Semenciw RM, Mao Y, Wigle DT. Serum iron and risk of fatal acute myocardial infarction. Epidemiology 1994; 5: 243-46.
49. Tuomainen TP, Salonen R, Nyyssonen K, Salonen JT. Cohort study of relation between donating blood and risk of myocardial infarction in 2682 men in eastern Finland. BMJ 1997; 314: 793-94.
50. Salonen JT, Toumainen TP, Salonen R, Lakka TA, Nyyssonen K. Donation of blood is associated with reduced risk of myocardial infarction. The Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Epidemiol 1998; 148: 445-51.
51. Facchini FS, Saylor KL. Effect of iron depletion on cardiovascular risk factors: studies in carbohydrate-intolerant patients. Ann N Y Acad Sci 2002; 967: 342-51.
52. Salonen JT, Korpela H, Nyyssonen K et al. Lowering of body iron stores by blood letting and oxidation resistance of serum lipoproteins a randomized cross-over trial in male smokers. J Intern Med 1995; 237: 161-68.
53. Van Jaarsveld H, Pool GF. Beneficial effects of blood donation on high density lipoprotein concentration and the oxidative potential of low density lipoprotein. Atherosclerosis 2002; 161: 395-402.
54. Liao Y, Cooper RS, McGee DL. Iron status and coronary heart disease: negative findings from the NHANES 1 epidemiologic follow-up study. Am J Epidemiol 1994; 139: 704-12.
55. Sempos CT, Looker AC, Gillum RF, Makuc DM. Body iron stores and the risk of coronary heart disease. N Engl J Med 1994; 330: 1119-24.
56. Baer DM, Tekawa IS, Hurley LB. Iron stores are not associated with acute myocardial infarction. Circulation 1994; 89: 2915-18.
57. Corti MC, Guralnik JM, Salive ME et al. Serum iron level, coronary artery disease, and all-cause mortality in older men and women. Am J Cardiol 1997; 79: 120-27.
58. Ascherio A, Willett WC, Rimm EB, Giovannucci EL, Stampfer MJ. Dietary iron intake and risk of coronary disease among men. Circulation 1994; 89: 969-74.
59. Manttari M, Manninen V, Huttunen JK et al. Serum ferritin and ceruloplasmin as coronary risk factors. Eur Heart J 1994; 15: 1599-603.
60. Stampfer MJ, Grodstein F, Rosenberg I, Willett WC, Hennekens CH. A prospective study of plasma ferritin and risk of myocardial infarction in US physicians. Circulation 1993; 87: 688 (Abstract).
61. Meyers DG, Strickland D, Maloley PA, Seburg JK, Wilson JE, McManus BF. Possible association of a reduction in cardiovascular events with blood donation. Heart 1997; 78: 188-93.
62. Ascherio A, Rimm EB, Giovannucci E, Willett WC, Stampfer MJ. Blood donations and risk of coronary heart disease in men. Circulation 2001; 103: 52-57.
63. Haidari M, Javadi E, Sanati A, Hajilooi M, Ghanbili J. Association of increased ferritin with premature coronary stenosis in men. Clin Chem 2001; 47: 1666-72.
64. Say AE, Gursurer M, Yazicioglu MV, Ersek B. Impact of body iron status on myocardial perfusion, left ventricular function, and angiographic morphologic features in patients with hypercholesterolemia. Am Heart J 2002; 143: 257-64.
65. Eichner JE, Qi H, Moore WE, Schechter E. Iron measures in coronary angiography patients. Atherosclerosis 1998; 136: 241-45.
66. Duffy SJ, Biegelsen ES, Holbrook M et al. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 2001; 103: 2799-804.
67. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986; 74: 1399-406.
68. Pignoli P, Longo T. Evaluation of atherosclerosis with B-mode ultrasound imaging. J Nucl Med Allied Sci 1988; 32: 166-73.
69. Poli A, Tremoli E, Colombo A, Sirtori M, Pignoli P, Paoletti R. Ultrasonographic measurement of the common carotid artery wall thickness in hypercholesterolemic patients. A new model for the quantitation and follow-up of preclinical atherosclerosis in living human subjects. Atherosclerosis 1988; 70: 253-61.
70. Burke GL, Evans GW, Riley WA et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 1995; 26: 386-91.
71. Craven TE, Ryu JE, Espeland MA et al. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study. Circulation 1990; 82: 1230-42.
72. Wofford JL, Kahl FR, Howard GR, McKinney WM, Toole JF, Crouse JR III. Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. Arterioscler Thromb 1991; 11: 1786-94.
73. Riley WA, Barnes RW, Applegate WB et al. Reproducibility of noninvasive ultrasonic measurement of carotid atherosclerosis. The Asymptomatic Carotid Artery Plaque Study. Stroke 1992; 23: 1062-68.
74. Espeland MA, Craven TE, Riley WA, Corson J, Romont A, Furberg CD. Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke 1996; 27: 480-85.
75. Rauramaa R, Vaisanen S, Mercuri M, Rankinen T, Penttila I, Bond MG. Association of risk factors and body iron status to carotid atherosclerosis in middle-aged eastern Finnish men. Eur Heart J 1994; 15: 1020-27.
76. Moore M, Folsom AR, Barnes RW, Eckfeldt JH. No association between serum ferritin and asymptomatic carotid atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 1995; 141: 719-23.
77. Kiechl S, Aichner F, Gerstenbrand F et al. Body iron stores and presence of carotid atherosclerosis. Results from the Bruneck Study. Arterioscler Thromb 1994; 14: 1625-30.
78. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation 1997; 96: 3300-307.
79. Drueke T, Witko-Sarsat V, Massy Z et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106: 2212-17.
80. Rubinger D, Friedlaender MM, Silver J, Kopolovic Y, Czaczkes WJ, Popovtzer MM. Progressive vascular calcification with necrosis of extremities in hemodialysis patients: a possible role of iron overload. Am J Kidney Dis 1986; 7: 125-29.
81. Cranton E. Bypassing bypass: the new technique of chelation therapy. New York: Stein and Day, 1984: 75-83, 220-30.
82. Babu AN, Gonzalez-Pena H. Iron chelating agents are not useful in treating atherosclerosis. Ann Intern Med 1994; 121: 384-85.
83. McCord JM, Day ED Jr. Superoxide-dependent production of hydroxyl radical catalyzed by iron-EDTA complex. FEBS Lett 1978; 86: 139-42.
84. Sloth-Nielsen J, Guldager B, Mouritzen C et al. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. Am J Surg 1991; 162: 122-25.
85. Olszewer E, Sabbag FC, Carter JP. A pilot double-blind study of sodium-magnesium EDTA in peripheral vascular disease. J Natl Med Assoc 1990; 82: 173-77.
86. Zacharski LR, Chow B, Lavori PW et al. The iron (Fe) and atherosclerosis study (FeAST): a pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease. Am Heart J 2000; 139: 337-45.
87. Cook JD, Finch CA, Smith NJ. Evaluation of the iron status of a population. Blood 1976; 48: 449-55.
88. Magnusson MK, Sigfusson N, Sigvaldason H, Johannesson GM, Magnusson S, Thorgeirsson G. Low iron-binding capacity as a risk factor for myocardial infraction. Circulation 1994; 89: 102-108.
89. Cook JD, Lipschitz DA, Miles LE, Finch CA. Serum ferritin as a measure of iron stores in normal subjects. Am J Clin Nutr 1974; 27: 681-87.
90. Finch CA, Huebers H. Perspectives in iron metabolism. N Engl J Med 1982; 306: 1520-28.
91. Fleming DJ, Jacques PF, Massaro JM, D'Agostino RB Sr, Wilson PW, Wood RJ. Aspirin intake and the use of serum ferritin as a measure of iron status. Am J Clin Nutr 2001; 74: 219-26.
92. Ascherio A, Hunter DJ. Iron and myocardial infarction. Epidemiology 1994; 5: 135-37.
93. Zacharski LR, Ornstein DL, Woloshin S, Schwartz LM. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J 2000; 140: 98-104.
94. Ascherio A, Willett WC. Are body iron stores related to the risk of coronary heart disease? N Engl J Med 1994; 330: 1152-54.
95. Cook JD. Defining optimal body iron. Proc Nutr Soc 1999; 58: 489-95.
96. Cook JD. The measurement of serum transferrin receptor. Am J Med Sci 1999; 318: 269-76.